What is he best known for?
The fields of study he is best known for:
- Major depressive disorder
- Psychiatry
- Internal medicine
Psychiatry, Mood, Major depressive disorder, Evidence-based medicine and Clinical psychology are his primary areas of study.
Bipolar disorder, Treatment of bipolar disorder and Quetiapine are subfields of Psychiatry in which his conducts study.
His Quetiapine study combines topics from a wide range of disciplines, such as Asenapine and Divalproex.
His Mood research is multidisciplinary, relying on both Systematic review, Randomized controlled trial and Treatment-resistant depression.
Major depressive disorder is closely attributed to Clinical trial in his work.
The concepts of his Clinical psychology study are interwoven with issues in Cognitive therapy, Cognition and Depression.
His most cited work include:
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. (988 citations)
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009 (476 citations)
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (410 citations)
What are the main themes of his work throughout his whole career to date?
Psychiatry, Major depressive disorder, Depression, Clinical psychology and Internal medicine are his primary areas of study.
His Psychiatry study frequently links to adjacent areas such as Systematic review.
His work carried out in the field of Major depressive disorder brings together such families of science as Biomarker, Antidepressant, Escitalopram, Rating scale and Meta-analysis.
His Clinical psychology research includes elements of Mental health, Neurocognitive, Schizophrenia and Anxiety.
His Internal medicine study also includes
- Placebo and related Randomized controlled trial and Clinical trial,
- Olanzapine together with Body mass index and Anesthesia.
His study in the field of Treatment of bipolar disorder also crosses realms of Lamotrigine.
He most often published in these fields:
- Psychiatry (43.54%)
- Major depressive disorder (38.78%)
- Depression (32.65%)
What were the highlights of his more recent work (between 2019-2021)?
- Major depressive disorder (38.78%)
- Depression (32.65%)
- Internal medicine (22.45%)
In recent papers he was focusing on the following fields of study:
Roumen Milev mainly investigates Major depressive disorder, Depression, Internal medicine, Escitalopram and Clinical psychology.
Roumen Milev has included themes like Cognition, Psychomotor learning, Rating scale, Ketamine and Antidepressant in his Major depressive disorder study.
His study on Depression is covered under Psychiatry.
Roumen Milev is interested in Mood disorders, which is a field of Psychiatry.
His research investigates the connection with Internal medicine and areas like Psychological intervention which intersect with concerns in Electroencephalography and Treatment outcome.
His study looks at the intersection of Clinical psychology and topics like Risk factor with Cognitive skill, Working memory and Effects of sleep deprivation on cognitive performance.
Between 2019 and 2021, his most popular works were:
- Effect of fecal microbiota transplant on symptoms of psychiatric disorders: a systematic review (15 citations)
- Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report (10 citations)
- Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression (9 citations)
In his most recent research, the most cited papers focused on:
- Major depressive disorder
- Internal medicine
- Psychiatry
His primary areas of study are Major depressive disorder, Depression, Internal medicine, Antidepressant and Clinical psychology.
His Major depressive disorder research is multidisciplinary, incorporating elements of Escitalopram, Bipolar disorder, Electroconvulsive therapy and Rating scale.
The various areas that he examines in his Bipolar disorder study include Neurology, Cognition, Randomization and Treatment response.
His Depression research is under the purview of Psychiatry.
His Antidepressant study combines topics in areas such as Biomarker and Neuroimaging.
His research integrates issues of Eating disorders, Substance abuse, Transplantation and Mood in his study of Gut–brain axis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
